Clinical Oncology News: SABCS 2016: Everolimus Added to Fulvestrant Upped PFS in Postmenopausal HR+ Breast Ca Pts

Adding everolimus to fulvestrant in postmenopausal women with hormone receptor (HR)-positive/HER2-negative, aromatase inhibitor (AI)-resistant metastatic breast cancer improved progression-free survival (PFS) to 10.4 months, compared with 5.1 months for fulvestrant alone, in the randomized, double-blind, Phase II PrECOG 0102 trial.

Read the full  story at Clinical Oncology News

Share This Article!